DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

CD70 expression increased cytotoxicity of CD70 CAR NK cells against osteosarcoma; however, upregulation of CD70 had no effect on cytotoxicity.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments ...

Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the ...

There is no highly effective vaccine against tuberculosis (TB), which remains an infection of global concern. Charles ...